Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Clinical and Translational Epidemiology

The Clinical and Translational Epidemiology Branch in NCI’s Epidemiology and Genomics Research Program stimulates, promotes, and supports cancer epidemiologic research to identify clinical, genomic, and lifestyle factors that improve outcomes for cancer survivors.

We also support research that examines factors associated with cancer development among individuals with underlying diseases and conditions.


Research areas include

  • cancer survivor research
    • adverse events and late effects
    • diet/lifestyle factors
    • predictive, prognostic and genomic factors
    • pharmacoepidemiology and pharmacogenomics
  • clinical epidemiology and risk prediction

Program Directors

Investigators seeking grant funding for clinical and translational epidemiology projects are encouraged to contact scientific staff in the Clinical and Translational Epidemiology Branch (CTEB) with questions.

CTEB Program Directors

Featured Funding Opportunities

View all funding opportunities related to cancer control research.

Interest Areas

Learn more about CTEB’s interests in the following areas, relevant funding opportunity announcements, related EGRP events, and staff contacts.

Featured Resources

Current Initiatives

Keep up to date about the current Clinical and Translational Epidemiology projects and initiatives ongoing at EGRP.

A first step in addressing research gaps regarding cannabis and cancer is to understand the patterns and extent of cannabis use among cancer patients, including those undergoing or having recently completed active treatment. NCI's Division of Cancer Control and Population Sciences provided administrative supplements to 12 NCI-designated cancer centers to conduct surveys in over 12,000 ambulatory cancer patients to better understand patterns of cannabis use among cancer patients. The research sites will survey cancer patients currently receiving treatment, or recently completed treatment and include a diverse population by age, sex, race/ethnicity, geography, and tumor type. Results are expected in early 2022.

Investigators can view and download this questionnaire with core measures of cannabis use.